What is the 13F Pro Quality Score for CRON?

13F Pro ranks Cronos Group Inc. (CRON) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CRON's current score at https://13fpro.ai/company/CRON (free sign-up required for the full ranking).

Which hedge funds own the most CRON stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CRON include D. E. Shaw & Co.,, Chescapmanager, Toroso Investments,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/CRON as soon as new 13F filings post.

Where does 13F Pro source CRON data?

All Cronos Group Inc. fundamentals and ownership data come directly from SEC EDGAR. Cronos Group Inc. files with the SEC under CIK 1656472. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CRON in?

Cronos Group Inc. (CRON) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives CRON's revenue?

Per Cronos Group Inc.'s latest 10-Q filed with the SEC on 2026-08-06, the biggest revenue drivers are: Cannabis flower ($39.2M, +57% YoY); Cannabis extracts ($13.8M, +65% YoY); Other ($19K, -73% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/CRON.

What are CRON's largest expenses?

Cronos Group Inc.'s latest 10-Q reports these as the largest expense items: Cost of sales ($24.2M, +28% YoY); General and administrative ($10.8M, +3% YoY); Sales and marketing ($6.8M, +27% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is CRON research updated on 13F Pro?

CRON's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Cronos Group Inc.(CRON)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1656472 CRON stock profile & AI dashboard →

13F Pro Quality Score

67.8/100

Rank #346 of 2,961 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

90.0/100

Profitability

96.7/100

Balance Sheet

73.8/100

Earnings Quality

60.2/100

Free Cash Flow

81.4/100

Institutional Flow

23.1/100

Revenue Scale

22.3/100

Dilution Risk

25.4/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why CRON Scores 68/100

exact factor attribution · 2026-09-11

CRON's composite is driven by revenue growth and profitability, held back by scale and institutional flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+8.0 pts

90th pct

Profitability

+7.0 pts

97th pct

Free cash flow

+4.7 pts

81th pct

Capital efficiency

+2.4 pts

74th pct

Earnings growth

+1.4 pts

79th pct

Earnings quality

+1.0 pts

60th pct

Shareholder dilution

-1.2 pts

25th pct

Institutional flow

-1.3 pts

23th pct

Scale

-4.2 pts

22th pct

Latest change (2026-08-06): 49 → 59 · ↑ Free cash flow 33→73; ↑ Profit margin 66→83; despite ↓ Revenue growth 87→77

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in CRON

Events flagged as statistical outliers against CRON's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-06
CRON quality score jumped 10 points (49→59) on a new filing
View source filing →

CRON Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Cronos Group Inc. (CRON), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CRON at 67.8/100 on a 32-signal composite quality model, placing it at rank #346 of 2,961 stocks — the top 25% of the AI-ranked universe. CRON scores in the top quartile across profitability (96.7), revenue growth (90.0), free cash flow (81.4). Areas of concern include revenue scale (22.3) and institutional flow (23.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Cronos Group Inc. reports quarterly revenue of $53.0M, net income of $32.1M, free cash flow of $22.3M. Top institutional holders of CRON by reported 13-F value include D. E. Shaw, Chescapmanager, Toroso Investments, based on the most recent SEC filings. CRON trades on the Nasdaq exchange and files with the SEC under CIK 1656472. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRON daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cronos Group Inc. directly from SEC EDGAR. Cronos Group Inc.'s 13F Pro composite quality score has ranged between 25 and 68 since 2021, currently 67.8 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about Cronos Group Inc.

Quirks, history, and lore behind CRON — the kind of stuff that makes a stock memorable.

1
The Basics
A Canadian company in the healthcare sector · listed on Nasdaq · operating in a heavily regulated, plant-based consumer industry.
2
The Numbers
A small-cap with revenue in the tens of millions annually — big ambitions, modest returns, and a balance sheet kept alive partly by a major strategic investment from a global beverage giant.
3
The History
Founded in 2012 in Canada, it rode the wave of cannabis legalization to become one of the first pot companies to list on a major U.S. exchange.
4
The Secret
Altria Group — the tobacco conglomerate behind Marlboro — took a large equity stake in the company, betting that nicotine customers and cannabis customers might overlap nicely.
5
The Lore
Its name evokes the Greek god of time, which feels fitting for a company that has spent years waiting for U.S. federal cannabis reform that keeps not quite arriving.
6
The Giveaway
Its ticker symbol is literally a crow's call — CRON — and this Canadian cannabis producer has been growing, processing, and selling legal marijuana since before it was cool.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving CRON's Business? Latest 10-Q Breakdown

✓ 28/28 datapoints verified

AI-extracted from Cronos Group Inc.'s 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net revenue rose 58% YoY to $53.0M and the company swung to $35.7M net income from a $38.5M loss, driven by a mix shift toward excise-tax-free Israel and other-country flower sales that lifted gross margin to 54% from 43%.

Biggest Revenue Drivers

Cannabis flower$39.2M+57% YoY

Higher cannabis flower sales in Israel and other countries (Germany), which carry no excise taxes, and higher flower sales in Canada

Cannabis extracts$13.8M+65% YoY

Higher extract sales in the Canadian market

Biggest Revenue Drivers

Total revenue: $53.0M+58% YoY

Cannabis flower$39.2M+57% YoY

Higher cannabis flower sales in Israel and other countries (Germany), which carry no excise taxes, and higher flower sales in Canada

Cannabis extracts$13.8M+65% YoY

Higher extract sales in the Canadian market

Other$19K-73% YoY

Largest Expense Items

Cost of sales$24.2M+28% YoY

Higher sales volumes in the period

General and administrative$10.8M+3% YoY

Higher transaction costs related to the pending CanAdelaar acquisition and higher professional fees, partially offset by recovery of excise tax stamp penalties and lower anti-dumping and restatement litigation costs

Sales and marketing$6.8M+27% YoY

Higher trade marketing expenses and higher salaries and benefits

Research and development$1.2M+31% YoY

Increased testing, clinical study and other product development activity, plus higher salaries and benefits

Margins: Gross margin expanded to 54% from 43% a year ago, driven by higher average sales prices from a mix shift toward Israel and other excise-tax-free countries plus higher sales volumes spreading fixed overhead costs.

Watch Items from the Filing

Two major customers accounted for 44% of net revenue before excise taxes in Q2 2026, and 36% of accounts receivable was concentrated with two customers as of June 30, 2026 (up from 16% with one customer at year-end 2025).
Israel's Trade Levies Commissioner initiated a new anti-dumping investigation on August 5, 2026 alleging a ~125% prima facie dumping margin on Canadian cannabis imports, after terminating a prior probe on procedural grounds in July 2026.
Board renewed the share repurchase program for up to $50.0M (expiring May 2027); the company already repurchased $16.1M of shares in Q2 2026 and $32.9M year-to-date.
Proposed $10 million settlement of the 2019 restatement shareholder class action received preliminary court approval on August 4, 2026, though one Ontario plaintiff intends to oppose final approval.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$53.0M

Net Income

Q2 2026

$32.1M

Free Cash Flow

Q2 2026

$22.3M

ROIC

Q2 2026

2.8%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+24.6% YoY

$146.6MFY 2025

FY22 $86.7MFY23 $87.2MFY24 $117.6MFY25 $146.6M

Net Income

-123.0% YoY

$-9.4MFY 2025

FY22 $-168.7MFY23 $-74.0MFY24 $41.1MFY25 $-9.4M

Operating Income

+77.3% YoY

$-17.4MFY 2025

FY22 $-111.4MFY23 $-84.8MFY24 $-76.5MFY25 $-17.4M

EPS (Diluted)

-118.2% YoY

$-0.02FY 2025

FY22 $-0.45FY23 $-0.19FY24 $0.11FY25 $-0.02

Total Assets

+2.6% YoY

$1.20BFY 2025

FY22 $1.21BFY23 $1.14BFY24 $1.17BFY25 $1.20B

Op. Cash Flow

+37.3% YoY

$25.9MFY 2025

FY22 $-88.9MFY23 $-42.8MFY24 $18.8MFY25 $25.9M

Free Cash Flow

-97.7% YoY

$149.0KFY 2025

FY22 $-92.4MFY23 $-45.3MFY24 $6.4MFY25 $149.0K

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$146.6M +24.6%	$117.6M +34.8%	$87.2M +0.6%	$86.7M +34.4%	$64.6M +38.2%	$46.7M
Net Income	$-9.4M -123.0%	$41.1M +155.5%	$-74.0M +56.2%	$-168.7M +57.4%	$-396.1M -441.6%	$-73.1M
Operating Income	$-17.4M +77.3%	$-76.5M +9.8%	$-84.8M +23.9%	$-111.4M +61.8%	$-292.0M -33.1%	$-219.4M
EPS (Diluted)	$-0.02 -118.2%	$0.11 +157.9%	$-0.19 +57.8%	$-0.45 +57.9%	$-1.07 -409.5%	$-0.21
Total Assets	$1.20B +2.6%	$1.17B +2.3%	$1.14B -6.0%	$1.21B -13.2%	$1.40B -27.4%	$1.93B
Operating Cash Flow	$25.9M +37.3%	$18.8M +144.0%	$-42.8M +51.8%	$-88.9M +42.1%	$-153.6M -6.0%	$-144.9M
Free Cash Flow	$149.0K -97.7%	$6.4M +114.2%	$-45.3M +50.9%	$-92.4M +43.9%	$-164.8M +6.5%	$-176.3M

Get alerted when CRON's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cronos Group Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CRON

D. E. Shaw & Co., Inc.
$24.6M8,840,503 sh
Chescapmanager LLC
$22.1M7,942,737 sh
Toroso Investments, LLC
$10.5M3,767,849 sh
DIMENSIONAL FUND ADVISORS LP
$8.5M3,048,254 sh
MACKENZIE FINANCIAL CORP
$6.3M1,597,039 sh
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$5.5M1,992,855 sh
RENAISSANCE TECHNOLOGIES LLC
$4.8M1,742,149 sh
CIBC WORLD MARKET INC.
$3.8M1,383,299 sh
MMCAP International Inc. SPC
$2.8M999,490 sh
Quinn Opportunity Partners LLC
$2.7M969,033 sh

Fund	Value	Shares
D. E. Shaw & Co., Inc.	$24.6M	8,840,503
Chescapmanager LLC	$22.1M	7,942,737
Toroso Investments, LLC	$10.5M	3,767,849
DIMENSIONAL FUND ADVISORS LP	$8.5M	3,048,254
MACKENZIE FINANCIAL CORP	$6.3M	1,597,039
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$5.5M	1,992,855
RENAISSANCE TECHNOLOGIES LLC	$4.8M	1,742,149
CIBC WORLD MARKET INC.	$3.8M	1,383,299
MMCAP International Inc. SPC	$2.8M	999,490
Quinn Opportunity Partners LLC	$2.7M	969,033

Companies Similar to CRON

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

VCYT

VERACYTE, INC.

AI score

Similar quality profile · 3 shared holders

Baader Bank Aktiengesellschaft Empirical Asset Management, LLC SOA Wealth Advisors, LLC.

LMAT

LEMAITRE VASCULAR INC

AI score

Similar quality profile

TMDX

TransMedics Group, Inc.

AI score

Similar quality profile · 2 shared holders

Headlands Technologies LLC J. Safra Sarasin Holding AG

INVA

Innoviva, Inc.

AI score

Similar quality profile · 2 shared holders

Headlands Technologies LLC Ankerstar Wealth, LLC

VCEL

Vericel Corp

AI score

Similar quality profile · 2 shared holders

Valeo Financial Advisors, LLC Ankerstar Wealth, LLC

PLX

Protalix BioTherapeutics, Inc.

AI score

Similar quality profile · 1 shared holders

Main Street Financial Solutions, LLC

CPRX

CATALYST PHARMACEUTICALS, INC.

AI score

Similar quality profile · 3 shared holders

Shay Capital LLC OXFORD ASSET MANAGEMENT LLP Pure Financial Advisors, LLC

ELMD

Electromed, Inc.

AI score

Similar quality profile · 1 shared holders

Financial Perspectives, Inc

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CRON on your watchlist

Track score changes the day Cronos Group Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CRON a good stock to buy?

13F Pro's AI-powered analysis of Cronos Group Inc. (CRON) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CRON are available on the CRON stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CRON is classified as a small company.

Which hedge funds own CRON?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CRON. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cronos Group Inc.'s investment landscape.